Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
113.62
-4.91 (-4.14%)
Mar 31, 2025, 9:45 AM EDT - Market open

Company Description

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering novel therapies for the management of central nervous system (CNS) disorders in the United States.

The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.

It is also developing AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder.

The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation.

Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics, Inc.
Axsome Therapeutics logo
Country United States
Founded 2012
IPO Date Nov 19, 2015
Industry Biotechnology
Sector Healthcare
Employees 683
CEO Herriot Tabuteau

Contact Details

Address:
One World Trade Center, 22nd Floor
New York, New York 10007
United States
Phone 212 332 3241
Website axsome.com

Stock Details

Ticker Symbol AXSM
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001579428
CUSIP Number 05464T104
ISIN Number US05464T1043
Employer ID 45-4241907
SIC Code 2834

Key Executives

Name Position
Dr. Herriot Tabuteau M.D. Founder, Chairman, Chief Executive Officer and President
Nick Pizzie CPA, M.B.A. Chief Financial Officer
Mark L. Jacobson M.A. Chief Operating Officer
Hunter Murdock Esq. General Counsel and Secretary
Ari Maizel Chief Commercial Officer

Latest SEC Filings

Date Type Title
Mar 25, 2025 8-K Current Report
Mar 5, 2025 8-K Current Report
Mar 3, 2025 8-K Current Report
Feb 18, 2025 10-K Annual Report
Feb 18, 2025 8-K Current Report
Feb 14, 2025 144 Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 13, 2025 144 Filing
Feb 10, 2025 8-K Current Report
Jan 31, 2025 8-K Current Report